OR5M9 Inhibitors
OR5M9 inhibitors are a class of chemical compounds that specifically interact with and inhibit the activity of the olfactory receptor OR5M9, a G-protein-coupled receptor (GPCR) involved in the detection of volatile molecules. Olfactory receptors, like OR5M9, belong to a vast family of receptors that are expressed in the sensory neurons of the olfactory epithelium and play a central role in the sense of smell. OR5M9, in particular, is part of the class A rhodopsin-like GPCRs, and its activity is initiated by the binding of specific ligands, which trigger a signal transduction cascade that ultimately leads to sensory perception. Inhibitors of OR5M9 act by either competing with endogenous ligands or by causing allosteric modulation that prevents proper receptor activation. These compounds can be designed to mimic the structure of natural ligands or to bind to other functional domains of the receptor, thereby preventing its interaction with signaling proteins like G-proteins.
The molecular design of OR5M9 inhibitors often involves studying the receptor's binding pocket and ligand interaction sites through techniques such as molecular docking and computational modeling. Structural features such as hydrophobicity, charge distribution, and hydrogen bonding capacity are key considerations in the development of potent inhibitors. Furthermore, the synthesis of these inhibitors typically follows principles of organic chemistry aimed at maximizing selectivity and binding affinity while minimizing non-specific interactions with other olfactory receptors. Researchers often utilize high-throughput screening methods to identify novel inhibitors from large libraries of small molecules, which can then be optimized for increased efficacy in binding to OR5M9. These inhibitors are invaluable tools for studying olfactory signaling pathways at the molecular level, as they allow for precise control over receptor activity, thereby enabling detailed investigations into the molecular mechanisms underlying olfactory signal transduction.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A inhibits histone deacetylases, which could lead to hyperacetylation of histones near the OR5M9 gene, resulting in a chromatin conformation that does not support the transcriptional activation of OR5M9. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This compound could decrease the methylation of DNA within the promoter region of OR5M9. Demethylation may lead to the recruitment of histone modifiers that establish a transcriptionally repressive environment, thereby decreasing OR5M9 expression. | ||||||
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $95.00 $322.00 $663.00 $1438.00 | 6 | |
Rifampicin can bind specifically to bacterial RNA polymerase, and if OR5M9 were to be expressed in a prokaryotic system, this binding would obstruct the initiation of transcription, leading to a decrease in OR5M9 mRNA levels. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
This compound intercalates between DNA bases and could disrupt the elongation phase of mRNA synthesis for OR5M9 by preventing the progression of RNA polymerase along the DNA template. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 blocks the proteasomal degradation pathway, possibly leading to the stabilization of negative regulatory proteins that could bind to the OR5M9 promoter and repress its transcription. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $260.00 $1029.00 | 26 | |
Targeting RNA polymerase II in eukaryotic cells, alpha-amanitin would inhibit the transcription of OR5M9 by blocking the polymerase's ability to synthesize mRNA, leading to a decrease in OR5M9 protein synthesis. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
By binding to specific DNA sequences, Mithramycin A can displace transcriptional activators from the OR5M9 promoter or recruit repressors, which would result in a downregulation of OR5M9 transcription. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine disrupts lysosomal acidification, which could alter the cellular processing and maturation of transcription factors necessary for the expression of OR5M9, leading to reduced transcriptional activity of the gene. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin (Sirolimus) inhibits the mTOR pathway, which is crucial for cap-dependent translation initiation in eukaryotic cells; this could lead to a global reduction in cap-dependent mRNA translation, including that of OR5M9. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 inhibits phosphatidylinositol 3-kinase (PI3K), which could disrupt downstream AKT signaling and transcription factor activity that is necessary for the expression of OR5M9, ultimately resulting in decreased expression of the gene. | ||||||